BACKGROUND: In 2016, the response to a yellow fever outbreak in Angola and the Democratic Republic of Congo led to a global shortage of yellow fever vaccine. As a result, a fractional dose of the 17DD yellow fever vaccine (containing one fifth [0.1 ml] of the standard dose) was offered to 7.6 million children 2 years of age or older and nonpregnant adults in a preemptive campaign in Kinshasa. The goal of this study was to assess the immune response to the fractional dose in a large-scale campaign. METHODS: We recruited participants in four age strata at six vaccination sites. We assessed neutralizing antibody titers against yellow fever virus in blood samples obtained before vaccination and at 1 month and 1 year after vaccination, using a plaque reduction neutralization test with a 50% cutoff (PRNT50). Participants with a PRNT50 titer of 10 or higher were considered to be seropositive. Those with a baseline titer of less than 10 who became seropositive at follow-up were classified as having undergone seroconversion. Participants who were seropositive at baseline and who had an increase in the titer by a factor of 4 or more at follow-up were classified as having an immune response. RESULTS: Among 716 participants who completed the 1-month follow-up, 705 (98%; 95% confidence interval [CI], 97 to 99) were seropositive after vaccination. Among 493 participants who were seronegative at baseline, 482 (98%; 95% CI, 96 to 99) underwent seroconversion. Among 223 participants who were seropositive at baseline, 148 (66%; 95% CI, 60 to 72) had an immune response. Lower baseline titers were associated with a higher probability of having an immune response (P<0.001). Among 684 participants who completed the 1-year follow-up, 666 (97%; 95% CI, 96 to 98) were seropositive for yellow fever antibody. The distribution of titers among the participants who were seronegative for yellow fever antibody at baseline varied significantly among age groups at 1 month and at 1 year (P<0.001 for both comparisons). CONCLUSIONS: A fractional dose of the 17DD yellow fever vaccine was effective at inducing seroconversion in participants who were seronegative at baseline. Titers remained above the threshold for seropositivity at 1 year after vaccination in nearly all participants who were seropositive at 1 month after vaccination. These findings support the use of fractional-dose vaccination for outbreak control. (Funded by the U.S. Agency for International Development and the Centers for Disease Control and Prevention.).
BACKGROUND: In 2016, the response to a yellow fever outbreak in Angola and the Democratic Republic of Congo led to a global shortage of yellow fever vaccine. As a result, a fractional dose of the 17DDyellow fever vaccine (containing one fifth [0.1 ml] of the standard dose) was offered to 7.6 million children 2 years of age or older and nonpregnant adults in a preemptive campaign in Kinshasa. The goal of this study was to assess the immune response to the fractional dose in a large-scale campaign. METHODS: We recruited participants in four age strata at six vaccination sites. We assessed neutralizing antibody titers against yellow fever virus in blood samples obtained before vaccination and at 1 month and 1 year after vaccination, using a plaque reduction neutralization test with a 50% cutoff (PRNT50). Participants with a PRNT50 titer of 10 or higher were considered to be seropositive. Those with a baseline titer of less than 10 who became seropositive at follow-up were classified as having undergone seroconversion. Participants who were seropositive at baseline and who had an increase in the titer by a factor of 4 or more at follow-up were classified as having an immune response. RESULTS: Among 716 participants who completed the 1-month follow-up, 705 (98%; 95% confidence interval [CI], 97 to 99) were seropositive after vaccination. Among 493 participants who were seronegative at baseline, 482 (98%; 95% CI, 96 to 99) underwent seroconversion. Among 223 participants who were seropositive at baseline, 148 (66%; 95% CI, 60 to 72) had an immune response. Lower baseline titers were associated with a higher probability of having an immune response (P<0.001). Among 684 participants who completed the 1-year follow-up, 666 (97%; 95% CI, 96 to 98) were seropositive for yellow fever antibody. The distribution of titers among the participants who were seronegative for yellow fever antibody at baseline varied significantly among age groups at 1 month and at 1 year (P<0.001 for both comparisons). CONCLUSIONS: A fractional dose of the 17DDyellow fever vaccine was effective at inducing seroconversion in participants who were seronegative at baseline. Titers remained above the threshold for seropositivity at 1 year after vaccination in nearly all participants who were seropositive at 1 month after vaccination. These findings support the use of fractional-dose vaccination for outbreak control. (Funded by the U.S. Agency for International Development and the Centers for Disease Control and Prevention.).
Authors: Luiz Antonio Bastos Camacho; Marcos da Silva Freire; Maria da Luz Fernandes Leal; Savitri Gomes de Aguiar; Jussara Pereira do Nascimento; Takumi Iguchi; José de Azevedo Lozana; Roberto Henrique Guedes Farias Journal: Rev Saude Publica Date: 2004-10-18 Impact factor: 2.106
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Sonja J Olsen; Ruth A Karron; Daniel B Jernigan; Joseph S Bresee Journal: MMWR Recomm Rep Date: 2016-08-26
Authors: Thomas P Monath; Richard Nichols; W Tad Archambault; Linda Moore; Ron Marchesani; Jason Tian; Robert E Shope; Nicola Thomas; Robert Schrader; Dean Furby; Philip Bedford Journal: Am J Trop Med Hyg Date: 2002-05 Impact factor: 2.345
Authors: Reinaldo M Martins; Maria de Lourdes S Maia; Roberto Henrique G Farias; Luiz Antonio B Camacho; Marcos S Freire; Ricardo Galler; Anna Maya Yoshida Yamamura; Luiz Fernando C Almeida; Sheila Maria B Lima; Rita Maria R Nogueira; Gloria Regina S Sá; Darcy A Hokama; Ricardo de Carvalho; Ricardo Aguiar V Freire; Edson Pereira Filho; Maria da Luz Fernandes Leal; Akira Homma Journal: Hum Vaccin Immunother Date: 2013-01-30 Impact factor: 3.452
Authors: Tini Garske; Maria D Van Kerkhove; Sergio Yactayo; Olivier Ronveaux; Rosamund F Lewis; J Erin Staples; William Perea; Neil M Ferguson Journal: PLoS Med Date: 2014-05-06 Impact factor: 11.069
Authors: Ricardo Ishak; Marluísa de Oliveira Guimarães Ishak; Antonio Carlos R Vallinoto; Francisco De Paula Pinheiro Journal: Hum Vaccin Immunother Date: 2019-11-14 Impact factor: 3.452
Authors: Laura Matrajt; Julia Eaton; Tiffany Leung; Dobromir Dimitrov; Joshua T Schiffer; David A Swan; Holly Janes Journal: Nat Commun Date: 2021-06-08 Impact factor: 14.919
Authors: Bettie W Kareko; Brian L Booty; Chad D Nix; Zoe L Lyski; Mark K Slifka; Ian J Amanna; William B Messer Journal: J Infect Dis Date: 2020-06-11 Impact factor: 7.759